SBIR Phase I: A Novel Respiratory Bag-Valve-Mask Resuscitator

SBIR 第一阶段：新型呼吸袋-瓣膜-面罩复苏器

• 批准号: 2124771
• 负责人: Adam Scott
• 金额: $ 25.59万
• 依托单位: COMPACT MEDICAL SOLUTIONS LLC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2022-05-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2124771&HistoricalAwards=false
• 关键词: SBIR; Phase; Novel; Respiratory; Bag

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of a novel resuscitator to ventilate patients with respiratory failure or cardiac arrest. With almost 300,000 cases of out-of-hospital cardiac arrest and approximately 350,000 in-hospital cases each year in the United States, a modest increase of just 5% in the number of patients surviving cardiac arrest would correspond to more than 33,000 additional lives saved. In 2017, the combined direct and indirect costs of deaths from out-of-hospital cardiac arrest for patients under 50 years of age to be $455 billion, with an estimate of $1.8 trillion for all deaths from cardiac arrest. On this basis, every 1% increase in the out-of-hospital cardiac arrest survival rate would result in a $4.5 billion cost saving to the United States economy.The proposed project addresses the technical challenges associated with a novel device.This Small Business Innovation Research (SBIR) Phase I project advance translation of a bag-valve-mask resuscitator that restricts the volume, pressure, and rate of ventilation to safe levels for any patient, from infant to adult. The goal of the project is to design and test a fully functioning prototype that incorporates an easy-to-use mechanism for quickly and simultaneously adjusting both the maximum volume of air delivered and the maximum pressure, and a mechanism for restricting ventilation rate. The project objectives are: (1) prototype and test a novel dial-operated mechanism for simultaneous volume and pressure control; (2) test a flow-based mechanism for restricting the ventilation rate; (3) compare the prototype performance with that of a standard bag-valve-mask resuscitator used by a group of trained medical personnel. Successful completion of this project will result in a fully functional prototype, a valuable set of data on the device performance, and important feedback from end-users on design, ease of use, and device functionality to inform future modifications.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I期项目的更广泛的影响/商业潜力是开发一种新型复苏者，以通风呼吸道衰竭或心脏骤停患者。 在美国，每年近30万例院外心脏骤停和大约350,000例院内病例，幸存的心脏骤停的患者数量仅增加5％，这将与33,000多人挽救的生命相对应。 2017年，50岁以下患者的院外心脏骤停的直接和间接死亡成本为4550亿美元，估计所有因心脏骤停的死亡而估计为1.8万亿美元。 On this basis, every 1% increase in the out-of-hospital cardiac arrest survival rate would result in a $4.5 billion cost saving to the United States economy.The proposed project addresses the technical challenges associated with a novel device.This Small Business Innovation Research (SBIR) Phase I project advance translation of a bag-valve-mask resuscitator that restricts the volume, pressure, and rate of ventilation to safe levels for any patient, from infant to adult.该项目的目的是设计和测试一个功能齐全的原型，该原型结合了一种易于使用的机制，可快速，同时调整最大空气量和最大压力，以及限制通风率的机制。项目目标是：（1）原型和测试一种同时体积和压力控制的新型拨号操作机制； （2）测试一种基于流动的机制，以限制通风速率； （3）将原型性能与一组训练有素的医务人员使用的标准袋式面具复苏器的原型性能进行比较。该项目的成功完成将导致功能齐全的原型，一套有关设备性能的宝贵数据以及最终用户的重要反馈，以设计，易用性和设备功能，以告知未来的修改。该奖项反映了NSF的法定任务，并通过使用该基金会的知识优点和广泛影响来评估NSF的法定任务。